Trial Profile
A Multi-center, Open-label, Randomised, Two-arm Phase III Trial of the Effect on Progression Free Survival of Bevacizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin liposomal; Paclitaxel; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms AURELIA
- Sponsors Roche
- 03 Jul 2019 Results from a nomogram model developed to improve prediction of overall survival in patients treated with chemotherapy in the AURELIA and CARTAXHY studies published in the European Journal of Cancer.
- 18 Apr 2018 Results from AURELIA and NCT01688206 studies, presented at the 109th Annual Meeting of the American Association for Cancer Research
- 12 Sep 2017 Results of landmark analysis of overall survival in platinum-resistant ovarian cancer patients from AURELIA study presented at the 42nd European Society for Medical Oncology Congress